(Reuters) – Amylyx Pharmaceuticals Inc’s drug for amyotrophic lateral sclerosis (ALS) won the support of external advisers to the U.S. Food and Drug Administration on Wednesday.
The FDA panel voted 7 to 2 in favor of the oral drug, AMX0035, citing the unmet need for more treatments against the fatal neurodegenerative condition commonly known as Lou Gehrig’s disease.
(Reporting by Leroy Leo and Mrinalika Roy in Bengaluru; Editing by Devika Syamnath)
